Angioedema Treatment Market By Treatment Type (Medications, Intravenous Immunoglobulin (IVIG), C1 Esterase Inhibitors, Antihistamines, Corticosteroids), By Drug Class (C1 Esterase Inhibitors, Bradykinin Receptor Antagonists, Antihistamines, Corticosteroids), By Route of Administration (Oral, Intravenous, Subcutaneous), By End-User (Hospitals, Clinics, Home Care Services), and By Region; Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Angioedema Treatment Market was valued at USD 4.8 billion in 2023 and will surpass USD 9.3 billion by 2030; growing at a CAGR of 9.9% during 2024 - 2030.

The Angioedema Treatment Market is witnessing notable growth driven by an increase in the global prevalence of angioedema, a condition characterized by the swelling of deeper layers of the skin, often around the eyes and lips. This condition can occur due to various underlying causes, including allergic reactions, hereditary angioedema (HAE), or acquired conditions related to the immune system. The market for angioedema treatments is expanding as new therapies emerge to address the diverse causes of the condition. The market is segmented into treatment type, drug class, route of administration, and end-users, each of which plays a critical role in shaping the evolution of therapeutic strategies. Below, we explore the key sub-segments that are driving the growth of the market.

Medications Segment Is Largest Due to Accessibility and Efficacy

In the treatment type segment, medications are the largest sub-segment in the angioedema treatment market. Medications remain the first line of treatment for most forms of angioedema, especially in managing symptoms of swelling and inflammation. Depending on the underlying cause, treatments may include C1 esterase inhibitors, antihistamines, corticosteroids, and other biologic or targeted therapies. These drugs work by addressing the root cause of the swelling, whether it’s an allergic reaction, an immune disorder, or a hereditary condition.

Medications are particularly popular due to their wide availability, ease of use, and efficacy in reducing symptoms. The growing understanding of angioedema pathophysiology has led to the development of more targeted therapies, improving patient outcomes. As the incidence of angioedema continues to rise globally, medications will continue to be the most widely prescribed treatment option for managing acute and chronic cases of the condition, solidifying their dominance in the market.

C1 Esterase Inhibitors Are Fastest Growing Due to Effective Management of Hereditary Angioedema

Among the drug classes, C1 esterase inhibitors represent the fastest growing sub-segment in the angioedema treatment market. These inhibitors are essential in the treatment of hereditary angioedema (HAE), a genetic condition that causes episodes of severe swelling, often in the extremities, face, or airways. C1 esterase inhibitors work by replacing or augmenting the activity of the missing or dysfunctional C1 inhibitor protein in patients with HAE, effectively reducing the frequency and severity of attacks.

The growing demand for targeted treatments in hereditary angioedema, particularly for patients who experience frequent or severe attacks, is driving the expansion of the C1 esterase inhibitors market. Additionally, the availability of newer, more convenient forms of C1 esterase inhibitors, such as subcutaneous formulations, is contributing to the rapid adoption of these therapies. As the diagnosis of HAE improves and awareness of the condition increases, C1 esterase inhibitors are expected to see continued growth as the treatment of choice for managing hereditary angioedema.

Oral Route of Administration Is Largest Due to Convenience and Patient Preference

In the route of administration segment, oral administration is the largest sub-segment, largely due to its convenience and ease of use for patients. Oral medications such as antihistamines and corticosteroids are commonly prescribed to manage symptoms of angioedema, particularly when the condition is not severe or in the case of allergic reactions. Oral therapies are easy to administer at home, providing patients with greater independence and reducing the need for frequent hospital visits or injections.

The increasing preference for oral medications, particularly for long-term management of chronic conditions or mild to moderate angioedema, is helping to sustain the dominance of this route of administration in the market. Furthermore, oral medications are often cost-effective and accessible, making them a favored option for both patients and healthcare providers. As the market for angioedema treatment continues to grow, the oral route will likely remain the most widely used due to its practical advantages.

Hospitals End-User Segment Is Largest Due to Acute Cases and Specialized Care

In the end-user segment, hospitals represent the largest sub-segment in the angioedema treatment market. Hospitals play a central role in the management of acute angioedema episodes, especially those caused by hereditary angioedema (HAE), severe allergic reactions, or other underlying conditions. Patients experiencing severe swelling or life-threatening complications, such as airway obstruction, often require immediate hospitalization and specialized care.

Hospitals are equipped with advanced diagnostic tools, emergency care facilities, and healthcare professionals trained to manage severe angioedema cases. Additionally, hospitals have the infrastructure necessary for administering intravenous treatments, such as C1 esterase inhibitors or intravenous immunoglobulin (IVIG), which are commonly used for managing acute and severe episodes. The high volume of patients requiring acute treatment in hospital settings continues to drive the demand for angioedema therapies, solidifying hospitals as the largest end-user segment.

North America Is Largest Region Due to Advanced Healthcare Infrastructure

North America is the largest regional market for angioedema treatments, largely due to its advanced healthcare infrastructure and high levels of awareness regarding rare conditions like hereditary angioedema. The United States, in particular, is a major contributor to the region's market share, with a well-established healthcare system that supports the diagnosis and treatment of complex conditions such as angioedema. The growing focus on precision medicine and targeted therapies in North America has further accelerated the adoption of advanced treatments for angioedema.

In addition, North America’s strong presence of pharmaceutical companies and healthcare providers, along with well-developed reimbursement policies, has made the region an attractive market for both local and international companies. The increasing awareness of angioedema, particularly hereditary angioedema, and the rising demand for effective treatment options contribute to North America’s position as the largest market for angioedema treatments.

Leading Companies & Competitive Landscape

The angioedema treatment market is highly competitive, with several key players driving innovation and market growth. Leading pharmaceutical companies, including Shire (now part of Takeda), CSL Behring, and Roche, are at the forefront of developing therapies such as C1 esterase inhibitors and intravenous immunoglobulin (IVIG) treatments for hereditary and acquired angioedema. These companies are investing heavily in research and development to improve the efficacy, safety, and convenience of angioedema treatments.

The market is also characterized by the emergence of newer, more targeted therapies, such as bradykinin receptor antagonists, which have demonstrated promising results in treating acute angioedema episodes. Additionally, companies are focusing on expanding their portfolios by introducing alternative forms of administration, such as subcutaneous formulations, to offer patients more convenient treatment options.

Recent Developments:

• Shire Pharmaceuticals (now part of Takeda) launched a new treatment for hereditary angioedema, improving patient outcomes in acute attacks.
• Sanofi received FDA approval for a new subcutaneous C1 esterase inhibitor aimed at preventing hereditary angioedema attacks.
• CSL Behring announced a partnership with a biotechnology firm to co-develop a new therapy targeting bradykinin receptors for angioedema treatment.
• Ferring Pharmaceuticals launched a new intranasal formulation for managing acute attacks of angioedema, providing a faster relief option.
• Biocryst Pharmaceuticals revealed the successful completion of clinical trials for a new oral treatment option for hereditary angioedema.

List of Leading Companies:

• Shire Pharmaceuticals (now part of Takeda)
• Sanofi S.A.
• CSL Behring
• Ferring Pharmaceuticals
• Pharming Group
• Biocryst Pharmaceuticals
• Eli Lilly and Company
• Roche Holding AG
• AbbVie Inc.
• Grifols
• Meda Pharmaceuticals (Mylan)
• Vertex Pharmaceuticals
• Bayer AG
• Amgen Inc.
• Teva Pharmaceuticals

Report Scope: